Abstract
Although multiple sclerosis (MS) is the most common demyelinating disorder of the central nervous system (CNS), it lacks any definitive diagnostic test. Instead, diagnosis of MS primarily depends upon clinical criteria, supported by abnormalities characteristic of MS on para-clinical investigations including magnetic resonance imaging of the brain and spine, in the absence of an alternative explanation for underlying neurologic symptoms. While many of the potential disorders that may mimic MS in routine clinical practice are either extremely rare, or associated with specific and characteristic distinguishing diagnostic features, some inflammatory demyelinating disorders of the CNS may be particularly challenging to distinguish from MS, especially during initial presentation. In particular, acute disseminated encephalomyelitis, neuromyelitis optica, and idiopathic transverse myelitis may closely resemble MS, impeding prompt and accurate diagnosis. In this review, we describe the clinical features, diagnosis, pathology, and treatment of these other CNS demyelinating disorders. In addition, we review relevant features of other CNS inflammatory disorders that may mimic MS, including Sjögren’s syndrome, systemic lupus erythematosus, Behçet’s disease, and primary CNS vasculitis.
Similar content being viewed by others
References
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. doi:10.1002/ana.22366
Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH (2008) Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 14(9):1157–1174. doi:10.1177/1352458508096878
de Seze J (2007) Multiple sclerosis: clinical aspects, acute disseminated encephalomyelitis, neuromyelitis optica and other inflammatory variants. Rev Neurol (Paris) 163(6–7):647–650
Torisu H, Kira R, Ishizaki Y, Sanefuji M, Yamaguchi Y, Yasumoto S, Murakami Y, Shimono M, Nagamitsu S, Masuzaki M, Amamoto M, Kondo R, Uozumi T, Aibe M, Gondo K, Hanai T, Hirose S, Matsuishi T, Shirahata A, Mitsudome A, Hara T (2010) Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev 32(6):454–462. doi:10.1016/j.braindev.2009.10.006
Tselis A, Lisak R (2005) Acute disseminated encephalomyelitis. In: Antel JP, Birnbaum G, Hartung HP, Vincent A (eds) Clinical neuroimmunology. Oxford University Press, New York, pp 147–171
Krupp LB, Banwell B, Tenembaum S (2007) Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 68(16 Suppl 2):S7–S12. doi:10.1212/01.wnl.0000259422.44235.a8
Brinar VV, Poser CM (2006) The spectrum of disseminated encephalomyelitis. Clin Neurol Neurosurg 108(3):295–310. doi:10.1016/j.clineuro.2005.11.017
Poser CM, Brinar VV (2004) Diagnostic criteria for multiple sclerosis: an historical review. Clin Neurol Neurosurg 106(3):147–158. doi:10.1016/j.clineuro.2004.02.004
Kuker W, Ruff J, Gaertner S, Mehnert F, Mader I, Nagele T (2004) Modern MRI tools for the characterization of acute demyelinating lesions: value of chemical shift and diffusion-weighted imaging. Neuroradiology 46(6):421–426. doi:10.1007/s00234-004-1203-5
Callen DJ, Shroff MM, Branson HM, Li DK, Lotze T, Stephens D, Banwell BL (2009) Role of MRI in the differentiation of ADEM from MS in children. Neurology 72(11):968–973. doi:10.1212/01.wnl.0000338630.20412.45
Ben Sira L, Miller E, Artzi M, Fattal-Valevski A, Constantini S, Ben Bashat D (2010) 1H-MRS for the diagnosis of acute disseminated encephalomyelitis: insight into the acute-disease stage. Pediatr Radiol 40(1):106–113. doi:10.1007/s00247-009-1372-9
Stuve O, Nessler S, Hartung HP, Hemmer B, Wiendl H, Kieseier BC (2005) Acute disseminated encephalomyelitis: pathogenesis, diagnosis, treatment, and prognosis. Nervenarzt 76(6):701–707. doi:0.1007/s00115-004-1842-0
Franciotta D, Columba-Cabezas S, Andreoni L, Ravaglia S, Jarius S, Romagnolo S, Tavazzi E, Bergamaschi R, Zardini E, Aloisi F, Marchioni E (2008) Oligoclonal IgG band patterns in inflammatory demyelinating human and mouse diseases. J Neuroimmunol 200(1–2):125–128. doi:10.1016/j.jneuroim.2008.06.004
Reindl M, Khalil M, Berger T (2006) Antibodies as biological markers for pathophysiological processes in MS. J Neuroimmunol 180(1–2):50–62. doi:10.1016/j.jneuroim.2006.06.028
Lalive PH, Hausler MG, Maurey H, Mikaeloff Y, Tardieu M, Wiendl H, Schroeter M, Hartung HP, Kieseier BC, Menge T (2011) Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler 17(3):297–302. doi:10.1177/1352458510389220
Tardieu M, Mikaeloff Y (2004) What is acute disseminated encephalomyelitis (ADEM)? Eur J Paediatr Neurol 8(5):239–242. doi:10.1016/j.ejpn.2004.05.006
Rodriguez M, Powell H, Lampert W (1983) Demyelination and leukodystrophy in the clinical neurosciences. In: Rosenberg R, Schoclet S (eds) Neuropathology, vol III. Churchill Livinstone, New York, pp 419–443
Stricker RB, Miller RG, Kiprov DD (1992) Role of plasmapheresis in acute disseminated (post-infectious) encephalomyelitis. J Clin Apher 7(4):173–179
Straub J, Chofflon M, Delavelle J (1997) Early high-dose intravenous methylprednisolone in acute disseminated encephalomyelitis: a successful recovery. Neurology 49(4):1145–1147
Dalakas MC (1998) Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 51(6 Suppl 5):S2–S8
Sahlas DJ, Miller SP, Guerin M, Veilleux M, Francis G (2000) Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology 54(6):1370–1372
Kleiman M, Brunquell P (1995) Acute disseminated encephalomyelitis: response to intravenous immunoglobulin. J Child Neurol 10(6):481–483
Bala B, Banwell B (2010) Cognitive and behavioural outcomes in individuals with a history of childhood acute disseminated encephalomyelitis. 62nd Annual Meeting, American Academy of Neurology, Toronto, pp IN2-2.005
Donmez FY, Aslan H, Coskun M (2009) Evaluation of possible prognostic factors of fulminant acute disseminated encephalomyelitis (ADEM) on magnetic resonance imaging with fluid-attenuated inversion recovery (FLAIR) and diffusion-weighted imaging. Acta Radiol 50(3):334–339. doi:10.1080/02841850902736617
Banwell BL (2007) The long (-itudinally extensive) and the short of it: transverse myelitis in children. Neurology 68(18):1447–1449. doi:10.1212/01.wnl.0000264553.99997.45
Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B (2001) Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology 56(10):1313–1318
Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66(10):1485–1489. doi:10.1212/01.wnl.0000216139.44259.74
Jacob A, Matiello M, Wingerchuk DM, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) Neuromyelitis optica: changing concepts. J Neuroimmunol 187(1–2):126–138. doi:10.1016/j.jneuroim.2007.04.009
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6(9):805–815. doi:10.1016/S1474-4422(07)70216-8
Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53(5):1107–1114
Ghezzi A, Bergamaschi R, Martinelli V, Trojano M, Tola MR, Merelli E, Mancardi L, Gallo P, Filippi M, Zaffaroni M, Comi G (2004) Clinical characteristics, course and prognosis of relapsing Devic’s Neuromyelitis Optica. J Neurol 251(1):47–52. doi:10.1007/s00415-004-0271-0
Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO (2011) A population-based study of neuromyelitis optica in Caucasians. Neurology 76(18):1589–1595. doi:10.1212/WNL.0b013e3182190f74
Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA (2006) Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63(7):964–968. doi:10.1001/archneur.63.7.964
Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202(4):473–477. doi:10.1084/jem.20050304
Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364(9451):2106–2112. doi:10.1016/S0140-6736(04)17551-X
Eckstein C, Syc S, Saidha S (2011) Differential diagnosis of longitudinally extensive transverse myelitis in adults. Eur Neurol J 3(1):27–39
Matsuoka T, Matsushita T, Osoegawa M, Ochi H, Kawano Y, Mihara F, Ohyagi Y, Kira J (2008) Heterogeneity and continuum of multiple sclerosis in Japanese according to magnetic resonance imaging findings. J Neurol Sci 266(1–2):115–125
Kira J (2003) Multiple sclerosis in the Japanese population. Lancet Neurol 2(2):117–127
Nakashima I, Fujihara K, Miyazawa I, Misu T, Narikawa K, Nakamura M, Watanabe S, Takahashi T, Nishiyama S, Shiga Y, Sato S, Weinshenker BG, Itoyama Y (2006) Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry 77(9):1073–1075. doi:10.1136/jnnp.2005.080390
Weinshenker BG, Wingerchuk DM, Nakashima I, Fujihara K, Lennon VA (2006) OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol 5(2):110–111
Kira J (2008) Neuromyelitis optica and Asian phenotype of multiple sclerosis. Ann N Y Acad Sci 1142:58–71
Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H (2002) A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 125(Pt 7):1450–1461
Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, Mandler RN, Weinshenker BG, Pittock SJ, Wingerchuk DM, Lucchinetti CF (2007) Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130(Pt 5):1194–1205. doi:10.1093/brain/awl371
Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, Takahashi T, Nakashima I, Takahashi H, Itoyama Y (2007) Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130(Pt 5):1224–1234. doi:10.1093/brain/awm047
Papeix C, Vidal JS, de Seze J, Pierrot-Deseilligny C, Tourbah A, Stankoff B, Lebrun C, Moreau T, Vermersch P, Fontaine B, Lyon-Caen O, Gout O (2007) Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 13(2):256–259. doi:10.1177/1352458506070732
Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64(7):1270–1272. doi:10.1212/01.WNL.0000159399.81861.D5
Capobianco M, Malucchi S, di Sapio A, Gilli F, Sala A, Bottero R, Marnetto F, Doriguzzi Bozzo C, Bertolotto A (2007) Variable responses to rituximab treatment in neuromyelitis optica (Devic’s disease). Neurol Sci 28(4):209–211. doi:10.1007/s10072-007-0823-z
Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. doi:10.1001/archneurol.2011.154
Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld R, Kuempfel T (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76(15):1310–1315. doi:10.1212/WNL.0b013e3182152881
Neuhaus O, Wiendl H, Kieseier BC, Archelos JJ, Hemmer B, Stuve O, Hartung HP (2005) Multiple sclerosis: mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 168(1–2):128–137. doi:10.1016/j.jneuroim.2005.01.024
Chan A, Weilbach FX, Toyka KV, Gold R (2005) Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 139(1):152–158. doi:10.1111/j.1365-2249.2005.02653.x
Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, Kim HJ, Bar-Or A (2007) Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 178(10):6092–6099
Kim SH, Kim W, Park MS, Sohn EH, Li XF, Kim HJ (2011) Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 68(4):473–479. doi:10.1001/archneurol.2010.322
Shimizu Y, Yokoyama K, Misu T, Takahashi T, Fujihara K, Kikuchi S, Itoyama Y, Iwata M (2008) Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol 255(2):305–307. doi:10.1007/s00415-007-0730-5
Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, Lucchinetti CF, Zephir H, Moder K, Weinshenker BG (2008) Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 65(1):78–83. doi:10.1001/archneurol.2007.17
Wingerchuk DM (2007) Diagnosis and treatment of neuromyelitis optica. Neurologist 13(1):2–11. doi:10.1097/01.nrl.0000250927.21903.f8
Transverse Myelitis Consortium Working Group (2002) Proposed diagnostic criteria, nosology of acute transverse myelitis. Neurology 59(4):499–505
Young J, Quinn S, Hurrell M, Taylor B (2009) Clinically isolated acute transverse myelitis: prognostic features and incidence. Mult Scler 15(11):1295–1302. doi:10.1177/1352458509345906
Altrocchi PH (1963) Acute transverse myelopathy. Arch Neurol 9:111–119
de Seze J, Lanctin C, Lebrun C, Malikova I, Papeix C, Wiertlewski S, Pelletier J, Gout O, Clerc C, Moreau C, Defer G, Edan G, Dubas F, Vermersch P (2005) Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology 65(12):1950–1953. doi:10.1212/01.wnl.0000188896.48308.26
Bruna J, Martinez-Yelamos S, Martinez-Yelamos A, Rubio F, Arbizu T (2006) Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases. Mult Scler 12(2):169–173
Alvarenga MP, Thuler LC, Neto SP, Vasconcelos CC, Camargo SG, Papais-Alvarenga RM (2010) The clinical course of idiopathic acute transverse myelitis in patients from Rio de Janeiro. J Neurol 257(6):992–998. doi:10.1007/s00415-009-5450-6
Pidcock FS, Krishnan C, Crawford TO, Salorio CF, Trovato M, Kerr DA (2007) Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology 68(18):1474–1480. doi:10.1212/01.wnl.0000260609.11357.6f
Perumal J, Zabad R, Caon C, MacKenzie M, Tselis A, Bao F, Latif Z, Zak I, Lisak R, Khan O (2008) Acute transverse myelitis with normal brain MRI: long-term risk of MS. J Neurol 255(1):89–93. doi:10.1007/s00415-007-0686-5
Scott TF (2007) Nosology of idiopathic transverse myelitis syndromes. Acta Neurol Scand 115(6):371–376. doi:10.1111/j.1600-0404.2007.00835.x
Morrissey SP, Miller DH, Kendall BE, Kingsley DP, Kelly MA, Francis DA, MacManus DG, McDonald WI (1993) The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study. Brain 116(Pt 1):135–146
Bashir K, Whitaker JN (2000) Importance of para-clinical and CSF studies in the diagnosis of MS in patients presenting with partial cervical transverse myelopathy and negative cranial MRI. Mult Scler 6(5):312–316
Chan KH, Tsang KL, Fong GC, Ho SL, Cheung RT, Mak W (2006) Idiopathic inflammatory demyelinating disorders after acute transverse myelitis. Eur J Neurol 13(8):862–868. doi:10.1111/j.1468-1331.2006.01376.x
Kaplin AI, Krishnan C, Deshpande DM, Pardo CA, Kerr DA (2005) Diagnosis and management of acute myelopathies. Neurologist 11(1):2–18. doi:10.1097/01.nrl.0000149975.39201.0b
Borchers AT, Gershwin ME (2011) Transverse myelitis. Autoimmun Rev. doi:10.1016/j.autrev.2011.05.018
Lipton HL, Teasdall RD (1973) Acute transverse myelopathy in adults: a follow-up study. Arch Neurol 28(4):252–257
Kaplin AI, Deshpande DM, Scott E, Krishnan C, Carmen JS, Shats I, Martinez T, Drummond J, Dike S, Pletnikov M, Keswani SC, Moran TH, Pardo CA, Calabresi PA, Kerr DA (2005) IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest 115(10):2731–2741. doi:10.1172/JCI25141
Jacob A, Weinshenker BG (2008) An approach to the diagnosis of acute transverse myelitis. Semin Neurol 28(1):105–120. doi:10.1055/s-2007-1019132
Greenberg BM, Thomas KP, Krishnan C, Kaplin AI, Calabresi PA, Kerr DA (2007) Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology 68(19):1614–1617. doi:10.1212/01.wnl.0000260970.63493.c8
Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46(6):878–886
Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P (2009) Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 15(4):487–492. doi:10.1177/1352458508100837
Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554–558
Kim SM, Waters P, Vincent A, Kim SY, Kim HJ, Hong YH, Park KS, Min JH, Sung JJ, Lee KW (2009) Sjögren’s syndrome myelopathy: spinal cord involvement in Sjögren’s syndrome might be a manifestation of neuromyelitis optica. Mult Scler 15(9):1062–1068. doi:10.1177/1352458509106636
Kim SM, Waters P, Vincent A, Kim SY, Kim HJ, Hong YH, Park KS, Min JH, Sung JJ, Lee KW (2009) Sjögren’s syndrome myelopathy: spinal cord involvement in Sjögren’s syndrome might be a manifestation of neuromyelitis optica. Mult Scler 15(9):1062–1068
Pericot I, Brieva L, Tintore M, Rio J, Sastre-Garriga J, Nos C, Montalban X (2003) Myelopathy in seronegative Sjögren syndrome and/or primary progressive multiple sclerosis. Mult Scler 9(3):256–259
Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D, Dubucquoi S, Pruvo JP, Vermersch P, Hatron PY (2004) Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 83(5):280–291
Binder A, Snaith ML, Isenberg D (1988) Sjögren’s syndrome: a study of its neurological complications. Br J Rheumatol 27(4):275–280
Pillemer SR, Matteson EL, Jacobsson LT, Martens PB, Melton LJ 3rd, O’Fallon WM, Fox PC (2001) Incidence of physician-diagnosed primary Sjögren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc 76(6):593–599
Alexander EL, Malinow K, Lejewski JE, Jerdan MS, Provost TT, Alexander GE (1986) Primary Sjögren’s syndrome with central nervous system disease mimicking multiple sclerosis. Ann Intern Med 104(3):323–330
Williams CS, Butler E, Roman GC (2001) Treatment of myelopathy in Sjögren syndrome with a combination of prednisone and cyclophosphamide. Arch Neurol 58(5):815–819
Jimenez S, Cervera R, Font J, Ingelmo M (2003) The epidemiology of systemic lupus erythematosus. Clin Rev Allergy Immunol 25(1):3–12. doi:10.1385/CRIAI:25:1:3
Joseph FG, Scolding N (2010) Neurolupus. Pract Neurol 10:4–15
Ellis SG, Verity MA (1979) Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955–1977. Semin Arthritis Rheum 8(3):212–221
Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ (2000) Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 59(2):120–124
Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, Hughes GR (2003) Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 30(5):985–992
Espinosa G, Mendizabal A, Minguez S, Ramo-Tello C, Capellades J, Olive A, Cervera R (2010) Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum 39(4):246–256. doi:10.1016/j.semarthrit.2008.09.002
Sherer Y, Hassin S, Shoenfeld Y, Levy Y, Livneh A, Ohry A, Langevitz P (2002) Transverse myelitis in patients with antiphospholipid antibodies–the importance of early diagnosis and treatment. Clin Rheumatol 21(3):207–210
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725. doi:10.1002/1529-0131(199709)40:9<1725:AID-ART29>3.0.CO;2-Y
Creamer P, Kirwan J (1992) Seronegative systemic lupus erythematosus. Br J Rheumatol 31(9):619–622
Joseph FG, Scolding NJ (2010) Neurolupus. Pract Neurol 10(1):4–15. doi:10.1136/jnnp.2009.200071
Propper DJ, Bucknall RC (1989) Acute transverse myelopathy complicating systemic lupus erythematosus. Ann Rheum Dis 48(6):512–515
Appenzeller S, Vasconcelos Faria A, Li LM, Costallat LT, Cendes F (2008) Quantitative magnetic resonance imaging analyses and clinical significance of hyperintense white matter lesions in systemic lupus erythematosus patients. Ann Neurol 64(6):635–643. doi:10.1002/ana.21483
Graham JW, Jan W (2003) MRI and the brain in systemic lupus erythematosus. Lupus 12(12):891–896
Boumpas DT, Patronas NJ, Dalakas MC, Hakim CA, Klippel JH, Balow JE (1990) Acute transverse myelitis in systemic lupus erythematosus: magnetic resonance imaging and review of the literature. J Rheumatol 17(1):89–92
Salmaggi A, Lamperti E, Eoli M, Venegoni E, Bruzzone MG, Riccio G, La Mantia L (1994) Spinal cord involvement and systemic lupus erythematosus: clinical and magnetic resonance findings in 5 patients. Clin Exp Rheumatol 12(4):389–394
Trevisani VF, Castro AA, Neves Neto JF, Atallah AN (2006) Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2:CD002265. doi:10.1002/14651858.CD002265.pub2
Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limon JM, Fuentes de la Mata J, Clark P, Vargas F, Alocer-Varela J (2005) Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 64(4):620–625. doi:10.1136/ard.2004.025528
Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M (2008) Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 59(12):1796–1804. doi:10.1002/art.24068
Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR (2007) Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2(5):968–975. doi:10.2215/CJN.01200307
Perry A, Vuitch F (1995) Causes of death in patients with sarcoidosis: a morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 119(2):167–172
Chapelon-Abric C (2001) Neurosarcoidosis. Ann Med Interne (Paris) 152(2):113–124
James DG (1967) Sarcoidosis. Curr Med Drugs 7(9):10–21
Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC (1997) Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 145(3):234–241
Vargas DL, Stern BJ (2010) Neurosarcoidosis: diagnosis and management. Semin Respir Crit Care Med 31(4):419–427. doi:10.1055/s-0030-1262210
Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, Scadding JW, Thompson EJ, Chamoun V, Miller DH, McDonald WI, Mitchell D (1999) Central nervous system sarcoidosis–diagnosis and management. Qjm 92(2):103–117
Hoitsma E, Faber CG, Drent M, Sharma OP (2004) Neurosarcoidosis: a clinical dilemma. Lancet Neurol 3(7):397–407. doi:10.1016/S1474-4422(04)00805-1
Lower EE, Weiss KL (2008) Neurosarcoidosis. Clin Chest Med 29 (3):475–492, ix. doi:10.1016/j.ccm.2008.03.016
Stern BJ, Krumholz A, Johns C, Scott P, Nissim J (1985) Sarcoidosis and its neurological manifestations. Arch Neurol 42(9):909–917
Cohen-Aubart F, Galanaud D, Grabli D, Haroche J, Amoura Z, Chalpelon-Abric C, Lyon-Caen O, Valeyre D, Piette JC (2010) Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore) 89(2):133–140
Dale JC, O’Brien JF (1999) Determination of angiotensin-converting enzyme levels in cerebrospinal fluid is not a useful test for the diagnosis of neurosarcoidosis. Mayo Clin Proc 74(5):535
Baughman RP, Iannuzzi MC (2000) Diagnosis of sarcoidosis: when is a peek good enough? Chest 117(4):931–932
Kouba DJ, Mimouni D, Rencic A, Nousari HC (2003) Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 148(1):147–148
Doty JD, Mazur JE, Judson MA (2003) Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest 124(5):2023–2026
Carter JD, Valeriano J, Vasey FB, Bognar B (2004) Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med 117(4):277–279
Duna GF, Calabrese LH (1995) Limitations of invasive modalities in the diagnosis of primary angiitis of the central nervous system. J Rheumatol 22(4):662–667
International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335(8697):1078–1080
Yazici H, Yurdakul S, Hamuryudan V (2001) Behçet disease. Curr Opin Rheumatol 13(1):18–22
Siva A, Altintas A, Saip S (2004) Behçet’s syndrome and the nervous system. Curr Opin Neurol 17(3):347–357
Al-Araji A, Kidd DP (2009) Neuro-Behçet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol 8(2):192–204
Mullins GM, Elamin M, Saidha S, Ali E, Jennings L, Counihan TJ, Hennessy M (2009) Acute aseptic meningitis and diffuse myelitis as the presenting features of neurological Behçet disease. J Clin Neurosci 16(12):1702–1704. doi:10.1016/j.jocn.2009.06.002
Akman-Demir G, Serdaroglu P, Tasci B (1999) Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients: the Neuro-Behçet study group. Brain 122(Pt 11):2171–2182
Serdaroglu P (1998) Behçet’s disease and the nervous system. J Neurol 245(4):197–205
Kidd D, Steuer A, Denman AM, Rudge P (1999) Neurological complications in Behçet’s syndrome. Brain 122(Pt 11):2183–2194
Saruhan-Direskeneli G, Yentur SP, Akman-Demir G, Isik N, Serdaroglu P (2003) Cytokines and chemokines in neuro-Behçet’s disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol 145(1–2):127–134
Yazici H, Fresko I, Yurdakul S (2007) Behçet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 3(3):148–155
Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C, Kocer N, Yazici H (2001) Behçet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 248(2):95–103
Kocer N, Islak C, Siva A, Saip S, Akman C, Kantarci O, Hamuryudan V (1999) CNS involvement in neuro-Behçet syndrome: an MR study. AJNR Am J Neuroradiol 20(6):1015–1024
Yesilot N, Mutlu M, Gungor O, Baykal B, Serdaroglu P, Akman-Demir G (2007) Clinical characteristics and course of spinal cord involvement in Behçet’s disease. Eur J Neurol 14(7):729–737
Kidd D, Beynon HL (2003) The neurological complications of systemic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 20(2):85–94
Kikuchi H, Aramaki K, Hirohata S (2008) Effect of infliximab in progressive neuro-Behçet’s syndrome. J Neurol Sci 272(1–2):99–105
Siva A, Fresko II (2000) Behçet’s disease. Curr Treat Options Neurol 2(5):435–448
Salvarani C, Brown RD Jr, Calamia KT, Christianson TJ, Weigand SD, Miller DV, Giannini C, Meschia JF, Huston J 3rd, Hunder GG (2007) Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol 62(5):442–451
Benseler S, Schneider R (2004) Central nervous system vasculitis in children. Curr Opin Rheumatol 16(1):43–50
Hajj-Ali RA, Singhal AB, Benseler S, Molloy E, Calabrese LH (2011) Primary angiitis of the CNS. Lancet Neurol 10(6):561–572. doi:10.1016/S1474-4422(11)70081-3
Calabrese LH, Duna GF, Lie JT (1997) Vasculitis in the central nervous system. Arthritis Rheum 40(7):1189–1201
Salvarani C, Brown RD Jr, Calamia KT, Christianson TJ, Huston J 3rd, Meschia JF, Giannini C, Miller DV, Hunder GG (2008) Primary central nervous system vasculitis: comparison of patients with and without cerebral amyloid angiopathy. Rheumatology (Oxford) 47(11):1671–1677
Lie JT (1992) Primary (granulomatous) angiitis of the central nervous system: a clinicopathologic analysis of 15 new cases and a review of the literature. Hum Pathol 23(2):164–171
Pomper MG, Miller TJ, Stone JH, Tidmore WC, Hellmann DB (1999) CNS vasculitis in autoimmune disease: MR imaging findings and correlation with angiography. AJNR Am J Neuroradiol 20(1):75–85
Harris KG, Tran DD, Sickels WJ, Cornell SH, Yuh WT (1994) Diagnosing intracranial vasculitis: the roles of MR and angiography. AJNR Am J Neuroradiol 15(2):317–330
Calabrese LH (2003) Clinical management issues in vasculitis: angiographically defined angiitis of the central nervous system—diagnostic and therapeutic dilemmas. Clin Exp Rheumatol 21(6 Suppl 32):S127–S130
Vollmer TL, Guarnaccia J, Harrington W, Pacia SV, Petroff OA (1993) Idiopathic granulomatous angiitis of the central nervous system: diagnostic challenges. Arch Neurol 50(9):925–930
Birnbaum J, Hellmann DB (2009) Primary angiitis of the central nervous system. Arch Neurol 66(6):704–709
Levy JA, Shimabukuro J, Hollander H, Mills J, Kaminsky L (1985) Isolation of AIDS-associated retroviruses from cerebrospinal fluid and brain of patients with neurological symptoms. Lancet 2(8455):586–588
Acknowledgments
Dr. Christopher Eckstein receives funding through a Sylvia Lawry Physician Fellowship from the National Multiple Sclerosis Society. Dr. Shiv Saidha has received consulting fees from MedicalLogix for the development of continuing medical education programs in neurology and has received educational grant support from TEVA Neurosciences. Dr. Michael Levy receives research funding from the Guthy Jackson Charitable Foundation.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
Christopher Eckstein and Shiv Saidha contributed equally to this work.
Rights and permissions
About this article
Cite this article
Eckstein, C., Saidha, S. & Levy, M. A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. J Neurol 259, 801–816 (2012). https://doi.org/10.1007/s00415-011-6240-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-011-6240-5